-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 22, Roche's Chugai Pharmaceutical and Noile-Immune Biotech jointly announced that they have signed a licensing agreement for Noile-Immune's proprietary PRIME CAR-T technology, which aims to use PRIME technology and Chugai's drug discovery technology to provide CAR-T cell therapy
The agreement is based on the results
CAR-T cell therapy has achieved significant success in the treatment of hematological tumors, but such cell therapies still face many challenges in the treatment of solid tumors, such as limited specific targets of solid tumors, difficulty of CAR-T cells infiltrating into solid tumors
Noile-Immune's PRIME technology promises to open up a new generation of CAR-T cell therapies that will not only be used in blood tumors, but also to treat solid tumors
Image credit: Noile-Immune.
Dr.
Original English:
Original English: